Newest studies

Current perspectives on postoperative cognitive dysfunction in geriatric patients: insights from clinical practice

45/100 ✓ Peer-reviewed Prevention trials Frontiers in medicine

Key finding: Recent research suggests that anti-inflammatory drugs and neuroprotective agents may be promising in preventing POCD. +1 more finding

Full summary, score breakdown and related studies → Original source

Association of Seizure Foci and Location of Tau and Amyloid Deposition and Brain Atrophy in Patients With Alzheimer Disease and Seizures

56/100 ✓ Peer-reviewed Biomarkers Neurology

Key finding: Our results reveal a spatial association between the epileptogenic focus and tau deposition, amyloid deposition, and neurodegeneration in early clinical stages of AD. +4 more findings

• Brain Scans

Full summary, score breakdown and related studies → Original source

The Microbiota-Gut-Brain Axis and Neurological Disorders: A Comprehensive Review

43/100 ✓ Peer-reviewed Disease mechanisms Life (Basel, Switzerland)

Key finding: The field of research on the gut-brain axis has grown significantly during the past two decades. +1 more finding

• Other Dementias

Full summary, score breakdown and related studies → Original source

SEC Charges Cassava Sciences and Former Top Executives with Securities Fraud Related to Alzheimer's Drug Clinical Trial

16/100 ⚠ Regulatory decision — not a study Laboratory science SEC Press Release / Administrative Order (Securities Act of 1933 Release No. 11311)

Key finding: Cassava Sciences agreed to pay a $40 million penalty +4 more findings

• Clinical Trials

Scored 21 on our rubric, shown as 16: non-peer-reviewed sources are capped at 16. See the breakdown.

Full summary, score breakdown and related studies → Original source

Ascertaining Out-of-Pocket Costs of Dementia Care: Feasibility Study of a Web-Based Weekly Survey

43/100 ✓ Peer-reviewed Costs and economics JMIR formative research

Key finding: Out-of-pocket costs of dementia care were collected via a web-based weekly survey for up to 18 months. +4 more findings

• Policy
• Caregiving

Full summary, score breakdown and related studies → Original source

Feasibility and acceptability of virtual programs for people with dementia and their caregivers

50/100 ✓ Peer-reviewed Risk factors BMC geriatrics

Key finding: The PWD and ICG interviews provided insight into the positive impacts of VP, challenges of VP, program barriers, program facilitating factors, and suggestions for future improvement for the OSCC55 + VPs. +3 more findings

• Caregiving

Full summary, score breakdown and related studies → Original source

Cerebrovascular disease is associated with Alzheimer's plasma biomarker concentrations in adults with Down syndrome

57/100 ✓ Peer-reviewed Biomarkers Brain communications

Key finding: There was a direct and indirect bidirectional effect through the glial fibrillary acidic protein of WMH on phosphorylated tau 217 concentration, which was associated with neurofilament light chain concentration in the entire sample. +2 more findings

• Biomarkers
• Down Syndrome

Full summary, score breakdown and related studies → Original source

NLRP3 inflammasome activation and pyroptosis are dispensable for tau pathology

43/100 ✓ Peer-reviewed Inflammation and the immune system Frontiers in aging neuroscience

Key finding: Activation of the NLRP3 pathway was observed in the mouse organotypic slice culture (OSC) model following stimulation with LPS and nigericin or exposure to tau seeds. +4 more findings

• Brain Biology

Full summary, score breakdown and related studies → Original source

GLP-1 analogue liraglutide attenuates CIH-induced cognitive deficits by inhibiting oxidative stress, neuroinflammation, and apoptosis via the Nrf2/HO-1 and MAPK/NF-κB signaling pathways

43/100 ✓ Peer-reviewed Drug development International immunopharmacology

Key finding: GLP-1 receptor agonist, known for promoting insulin secretion and reducing glucose levels, has demonstrated neuroprotective effects in various experimental models such as stroke, Alzheimer's disease, and Parkinson's disease. +4 more findings

• Brain Biology

Full summary, score breakdown and related studies → Original source

Transport of β-amyloid from brain to eye causes retinal degeneration in Alzheimer's disease

43/100 ✓ Peer-reviewed Brain scans and imaging The Journal of experimental medicine

Key finding: These results revealed brain-to-eye Aβ transport as a major contributor to AD retinopathy, highlighting a new therapeutic avenue in ocular and neurodegenerative disease.

• Brain Biology

Full summary, score breakdown and related studies → Original source

Glutamate Transporter 1 as a Novel Negative Regulator of Amyloid β

43/100 ✓ Peer-reviewed Biomarkers Cells

Key finding: These findings emphasize the potential of targeting the GLT-1/PS1 interaction as a novel therapeutic strategy for AD.

Full summary, score breakdown and related studies → Original source

Medicare Advantage Has Become Notorious for Prior Authorization—CMS and Lawmakers Are Taking Action

40/100 ✓ Peer-reviewed Health systems and care delivery JAMA

Key finding: This Medical News article discusses care denials under Medicare Advantage plans and efforts to streamline the prior authorization process.

• Policy

Full summary, score breakdown and related studies → Original source

Adopting a 'community of practice' between palliative and dementia care nurses

43/100 ✓ Peer-reviewed End-of-life care Nursing standard (Royal College of Nursing (Great Britain) : 1987)

Key finding: Dementia usually occurs as a result of brain disease and, while it is usually chronic or progressive in nature, it has not traditionally been conceptualised as a terminal or life-limiting syndrome.

• End-of-Life Care

Full summary, score breakdown and related studies → Original source

Benefits and risks of FDA-approved amyloid-targeting antibodies for treatment of early Alzheimer's disease: Navigating clinician-patient engagement

48/100 ✓ Peer-reviewed Treatments Alzheimer's & dementia : the journal of the Alzheimer's Association

Key finding: Effectively communicating the risks, benefits, burdens, costs, and available support associated with these novel disease-modifying treatments to patients, families, and other healthcare providers is essential but complex.

• Treatments

Full summary, score breakdown and related studies → Original source

Lipids, lipoproteins, and apolipoproteins: Associations with cognition and dementia

43/100 ✓ Peer-reviewed Risk factors Atherosclerosis

Key finding: We conclude that the evidence is primarily insufficient or conflicting, possibly due to nonoptimal study designs. +1 more finding

• Risk Factors
• Genetics
• Brain Biology

Full summary, score breakdown and related studies → Original source

How international experts would define advance care planning: a content analysis

52/100 ✓ Peer-reviewed End-of-life care Annals of palliative medicine

Key finding: In conclusion, international experts from 30 countries typically defined ACP as person-centered conversations to choose future care and treatment, without focusing on end of life or documentation.

• End-of-Life Care

Full summary, score breakdown and related studies → Original source

Clinical and Sociodemographic Characteristics of New Residents of Assisted Living: A Nested Case-Control Study

57/100 ✓ Peer-reviewed Health systems and care delivery Journal of the American Medical Directors Association

Key finding: There were 2427 new residents of assisted living who were matched to 9708 home care recipients [mean (SD) age 85.5 (6.02) years, 72% female]. +4 more findings

• Care Services

Full summary, score breakdown and related studies → Original source

Effect of long-term pharmacological treatments on Alzheimer disease: A systematic review and network meta-analysis

82/100 ✓ Peer-reviewed Treatments Medicine

Key finding: Seventeen RCTs, comprising 7214 participants, investigated the efficacy of the following drugs: Donepezil, Rivastigmine, Galantamine, Memantine, Ginkgo biloba extract (EGb), Atorvastatin-calcium and Vitamin B in the treatment of AD. +4 more findings

• Treatments

Full summary, score breakdown and related studies → Original source

Psychometric and adherence considerations for high-frequency, smartphone-based cognitive screening protocols in older adults

55/100 ✓ Peer-reviewed Cognitive tests and assessment Journal of the International Neuropsychological Society : JINS

Key finding: Average compliance by time of day ranged from 90.2% for morning sessions, to 77.9% for afternoon sessions, and 84.4% for evening sessions. +4 more findings

• Diagnosis
• Digital Tools

Full summary, score breakdown and related studies → Original source

MLKL-USP7-UBA52 signaling is indispensable for autophagy in brain through maintaining ubiquitin homeostasis

44/100 ✓ Peer-reviewed Biomarkers Autophagy

Key finding: Here, we observed significant compromise in macroautophagy/autophagy in the brains of mlkl knockout (KO) mice, as evidenced by the downregulation of BECN1/Beclin1 and ULK1 (unc-51 like autophagy activating kinase 1). +4 more findings

Full summary, score breakdown and related studies → Original source

Profiling aducanumab as a treatment option for Alzheimer's disease: an overview of efficacy, safety and tolerability

41/100 ✓ Peer-reviewed Treatments Expert review of neurotherapeutics

Key finding: Alzheimer's disease is the most common form of dementia worldwide. +1 more finding

• Treatments
• Side Effects

Full summary, score breakdown and related studies → Original source

Association of Adherence to a MIND-Style Diet With the Risk of Cognitive Impairment and Decline in the REGARDS Cohort

78/100 ✓ Peer-reviewed Prevention trials Neurology

Key finding: Greater MIND diet adherence was associated with decreased risk of cognitive impairment in female participants but not male participants, with no difference between Black participants and White participants. +4 more findings

• Lifestyle
• Risk Factors
• Health Equity

Full summary, score breakdown and related studies → Original source

SGLT2 Inhibitor Use and Risk of Dementia and Parkinson Disease Among Patients With Type 2 Diabetes

70/100 ✓ Peer-reviewed Prevention and risk Neurology

Key finding: In this nationwide population-based study, SGLT2i use significantly reduced the risks of neurodegenerative disorders in patients with type 2 diabetes independent of various factors including comorbidities and bioclinical parameters. +4 more findings

• Risk Factors

Full summary, score breakdown and related studies → Original source

Gut microbiota metabolites: potential therapeutic targets for Alzheimer's disease?

43/100 ✓ Peer-reviewed Disease mechanisms Frontiers in pharmacology

Key finding: The gut microbiota plays a crucial role in the pathogenesis of AD through continuous bidirectional communication via the microbiota-gut-brain axis. +4 more findings

• Brain Biology
• Treatments

Full summary, score breakdown and related studies → Original source

MIND Diet Impact on Multiple Sclerosis Patients: Biochemical Changes after Nutritional Intervention

57/100 ✓ Peer-reviewed Prevention and risk International journal of molecular sciences

Key finding: In the case-control stage (baseline evaluation), we found significant differences in fatigue scores (p < 0.001), adherence to the MIND diet (p < 0.001), the serum levels of brain-derived neurotrophic factor (BDNF) (p < 0.001), and higher oxidative status in the MS group, with lower levels of reduced glutathione (p < 0.001), reduced/oxidised glutathione ratio (p < 0.001), and elevated levels of lipoperoxidation (p < 0.002) and 8-hydroxy-2'-deoxyguanosine (p < 0.025).

• Lifestyle

Full summary, score breakdown and related studies → Original source